24.24
Catalyst Pharmaceuticals Inc stock is traded at $24.24, with a volume of 654.44K.
It is down -0.33% in the last 24 hours and down -0.82% over the past month.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
See More
Previous Close:
$24.32
Open:
$24
24h Volume:
654.44K
Relative Volume:
0.54
Market Cap:
$2.96B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
20.54
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+5.03%
1M Performance:
-0.82%
6M Performance:
+19.47%
1Y Performance:
+11.86%
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CPRX
Catalyst Pharmaceuticals Inc
|
24.24 | 2.97B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
Zacks Research Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-Buy - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup - ChartMill
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Rafferty Asset Management LLC - MarketBeat
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - Finviz
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance
Best Value Stocks to Buy for March 4th - Yahoo Finance Singapore
Catalyst Pharmaceuticals (CPRX) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
CPRX: Citigroup Raises Price Target to $35.00, Maintains Buy Rat - GuruFocus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Vanguard Group Inc. - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results - Insider Monkey
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns - Yahoo Finance
Why Catalyst Pharmaceuticals (CPRX) Is Down 5.0% After Issuing 2026 Guidance And Buyback PlanAnd What's Next - Sahm
CPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc (CPRX) Q4 2025 Earnings Call Highli - GuruFocus
Catalyst Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y - Finviz
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com India
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Catalyst Pharma Q4 Net Income Slips; Announces FY26 Outlook - RTTNews
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout - ChartMill
Catalyst Pharmaceuticals (CPRX) Net Margin Strength Reinforces Bullish Earnings Narrative - Sahm
Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT I - GuruFocus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat
Catalyst Pharmaceuticals Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook - TipRanks
Catalyst Pharmaceuticals (CPRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Revenue $152.6M, vs. FactSet Est of $142.7M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Adjusted EPS $0.68, vs. FactSet Est of $0.59 - marketscreener.com
Record 2025 growth and 2026 outlook at Catalyst Pharmaceuticals (Nasdaq: CPRX) - Stock Titan
CPRX | Catalyst Pharmaceutical Inc. FinancialsIncome Statement - Quiver Quantitative
Catalyst Pharmaceuticals Reports Record $589 Million in 2025 Revenues, Projects Continued Growth for 2026 - Quiver Quantitative
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times
Catalyst Pharmaceuticals Reports Record Fourth Quarter and - GlobeNewswire
Catalyst Pharmaceuticals earnings on deck amid growth questions - Investing.com Nigeria
Catalyst Pharmaceuticals earnings on deck amid growth questions By Investing.com - Investing.com Canada
Catalyst: Q4 Financial Results Overview - Bitget
Catalyst Pharmaceuticals, Inc. (CPRX): Strong Buy Ratings and 43% Potential Upside Propel Investor Interest - DirectorsTalk Interviews
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Aug Volume: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Upgrade & Verified Chart Pattern Signals - baoquankhu1.vn
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):